Invention Grant
- Patent Title: Glucokinase (GCK) iRNA compositions and methods of use thereof
-
Application No.: US17069907Application Date: 2020-10-14
-
Publication No.: US11859185B2Publication Date: 2024-01-02
- Inventor: Kevin Fitzgerald , David Erbe , Gregory Hinkle
- Applicant: Alnylam Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee: Alnylam Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Deborah L. Nagle
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12N15/113 ; A61K31/713 ; A61K45/06
Abstract:
The invention relates to double stranded ribonucleic acid (dsRNA) compositions targeting a glucokinase (GCK) gene, as well as methods of inhibiting expression of a glucokinase (GCK) gene, and methods of treating subjects having a glycogen storage disease (GSD), e.g., type Ia GSD.
Public/Granted literature
- US20210171956A1 GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF Public/Granted day:2021-06-10
Information query
